Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc (ATXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,462
  • Shares Outstanding, K 16,748
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,150 K
  • 60-Month Beta 0.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 45.39
Trade ATXI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +5.33%
on 09/21/21
1.8400 -14.13%
on 08/31/21
-0.0600 (-3.66%)
since 08/23/21
3-Month
1.5000 +5.33%
on 09/21/21
2.8100 -43.77%
on 07/01/21
-0.8300 (-34.44%)
since 06/23/21
52-Week
1.5000 +5.33%
on 09/21/21
11.3400 -86.07%
on 10/01/20
-9.4900 (-85.73%)
since 09/23/20

Most Recent Stories

More News
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study

Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.

IRWD : 13.00 (+0.08%)
BPTH : 5.39 (-0.55%)
ATXI : 1.5800 (+3.27%)
AMRX : 5.21 (+3.37%)
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

PFE : 44.04 (-0.34%)
GLMD : 3.04 (+0.66%)
TRIL : 17.45 (-0.23%)
ATXI : 1.5800 (+3.27%)
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Avenue Therapeutics, Inc. (NASDAQ: ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that it has received a second Complete Response...

ATXI : 1.5800 (+3.27%)
FBIO : 3.52 (+2.33%)
Housing Figures, Manufacturing Figures Due Next Week

Monday U.S. Featured Earnings NextDecade Corporation (NASDAQ: NEXT) (Q1) EPS projected for ...

GURU.TO : 16.68 (-1.59%)
NEXT.TO : 2.36 (+5.36%)
HEXO.TO : 2.46 (unch)
NEXT : 2.59 (-2.26%)
ATXI : 1.5800 (+3.27%)
ORCL : 89.00 (-0.47%)
HRB : 25.44 (+0.43%)
LZB : 33.63 (+0.18%)
LEN : 99.03 (-0.48%)
KR : 40.12 (-0.15%)
JBL : 61.00 (-0.78%)
CMC : 31.15 (-0.26%)
SWBI : 21.50 (-0.05%)
What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?

COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.

HCA : 255.53 (-1.05%)
CHE : 470.03 (-0.65%)
FLGT : 87.36 (-3.16%)
ATXI : 1.5800 (+3.27%)
BioRad (BIO) to Report Q1 Earnings: What's in the Cards?

Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.

HCA : 255.53 (-1.05%)
BIO : 797.34 (+1.49%)
ATXI : 1.5800 (+3.27%)
ELAN : 32.47 (+2.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...

ATXI : 1.5800 (+3.27%)
What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

PRGO : 42.77 (unch)
PCRX : 57.99 (+0.69%)
PETQ : 25.22 (+1.24%)
ATXI : 1.5800 (+3.27%)
ResMed (RMD) to Report Q3 Earnings: What's in the Offing?

Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.

IART : 72.33 (+1.69%)
HCA : 255.53 (-1.05%)
ATXI : 1.5800 (+3.27%)
ELAN : 32.47 (+2.11%)
LabCorp (LH) to Report Q1 Earnings: What's in the Offing?

With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.

LH : 296.74 (+1.81%)
HCA : 255.53 (-1.05%)
ATXI : 1.5800 (+3.27%)
ELAN : 32.47 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 1.6600
2nd Resistance Point 1.6200
1st Resistance Point 1.6000
Last Price 1.5800
1st Support Level 1.5400
2nd Support Level 1.5000
3rd Support Level 1.4800

See More

52-Week High 11.3400
Fibonacci 61.8% 7.5811
Fibonacci 50% 6.4200
Fibonacci 38.2% 5.2589
Last Price 1.5800
52-Week Low 1.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar